Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Thalassemia × fludarabine × Clear all

Phase

Status

Completed 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 43 Multiple Myeloma 23 Leukemia 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Myelodysplastic Syndromes 20 Lymphoma 20 Melanoma 19 Lymphoma, Non-Hodgkin 18 Leukemia, Lymphocytic, Chronic, B-Cell 18 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16 Neoplasms 13 Neoplasm Metastasis 12 Hodgkin Disease 12 Recurrence 10 Hematologic Neoplasms 10 Skin Neoplasms 8 Kidney Neoplasms 8 Ovarian Neoplasms 7 Neoplasms, Plasma Cell 7 Myeloproliferative Disorders 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma, Follicular 7 Lymphoma, B-Cell 7 Carcinoma, Non-Small-Cell Lung 7 Lymphoma, Mantle-Cell 6 Carcinoma, Renal Cell 6 Burkitt Lymphoma 6 Triple Negative Breast Neoplasms 5 Primary Myelofibrosis 4 Neuroblastoma 4

Interventions

fludarabine phosphate 2 Cyclophosphamide 2 fludarabine 1 Whole-Body Irradiation 1 Peripheral Blood Stem Cell Transplantation 1 Mesna 1 Busulfan 1 Alemtuzumab 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡